IL188923A0 - Method for predicting the response to a treatment - Google Patents

Method for predicting the response to a treatment

Info

Publication number
IL188923A0
IL188923A0 IL188923A IL18892308A IL188923A0 IL 188923 A0 IL188923 A0 IL 188923A0 IL 188923 A IL188923 A IL 188923A IL 18892308 A IL18892308 A IL 18892308A IL 188923 A0 IL188923 A0 IL 188923A0
Authority
IL
Israel
Prior art keywords
predicting
response
treatment
Prior art date
Application number
IL188923A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35511140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL188923(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL188923A0 publication Critical patent/IL188923A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
IL188923A 2005-08-12 2008-01-21 Method for predicting the response to a treatment IL188923A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05017663 2005-08-12
PCT/EP2006/004950 WO2007019899A2 (en) 2005-08-12 2006-05-24 Method for predicting the response to a treatment with a her dimerization inhibitor

Publications (1)

Publication Number Publication Date
IL188923A0 true IL188923A0 (en) 2008-08-07

Family

ID=35511140

Family Applications (1)

Application Number Title Priority Date Filing Date
IL188923A IL188923A0 (en) 2005-08-12 2008-01-21 Method for predicting the response to a treatment

Country Status (32)

Country Link
US (2) US7700299B2 (enExample)
EP (2) EP1915460B1 (enExample)
JP (1) JP2009504142A (enExample)
KR (2) KR20110074921A (enExample)
CN (2) CN101705287A (enExample)
AR (1) AR057323A1 (enExample)
AT (2) ATE539171T1 (enExample)
AU (2) AU2006281746B2 (enExample)
BR (1) BRPI0615001A2 (enExample)
CA (1) CA2616913A1 (enExample)
CL (1) CL2010000720A1 (enExample)
CR (1) CR9686A (enExample)
CY (1) CY1111612T1 (enExample)
DE (1) DE602006019265D1 (enExample)
DK (1) DK1915460T3 (enExample)
EC (1) ECSP088171A (enExample)
ES (1) ES2356066T3 (enExample)
HR (1) HRP20110171T1 (enExample)
IL (1) IL188923A0 (enExample)
MA (1) MA31549B1 (enExample)
MX (1) MX2008001926A (enExample)
NO (1) NO20080371L (enExample)
NZ (1) NZ565270A (enExample)
PL (1) PL1915460T3 (enExample)
PT (1) PT1915460E (enExample)
RS (1) RS51859B (enExample)
RU (2) RU2408735C2 (enExample)
SI (1) SI1915460T1 (enExample)
TW (1) TW200741010A (enExample)
UA (1) UA93989C2 (enExample)
WO (1) WO2007019899A2 (enExample)
ZA (1) ZA201102688B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
PT1282443E (pt) * 2000-05-19 2009-12-04 Genentech Inc Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
KR20110050567A (ko) 2004-07-22 2011-05-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060121044A1 (en) * 2004-12-07 2006-06-08 Genentech, Inc. Selecting patients for therapy with a her inhibitor
UA94899C2 (ru) * 2005-01-21 2011-06-25 Дженентек, Инк. Фиксированное дозирование антител к her
DK1850874T3 (da) * 2005-02-23 2013-11-11 Genentech Inc Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
JP2009505658A (ja) * 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
BRPI0808418A2 (pt) 2007-03-02 2014-07-22 Genentech, Inc Predição de resposta a um inibidor de her
JP5433189B2 (ja) * 2007-09-28 2014-03-05 承一 尾崎 Ｍｐｏ−ａｎｃａ関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法
CA2711843C (en) * 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
KR101642846B1 (ko) * 2007-12-26 2016-07-26 백시넥스 인코포레이티드 항-ｃ35 항체 병용 치료 및 방법
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
MX2010009940A (es) * 2008-03-14 2010-09-28 Genentech Inc Variaciones geneticas asociadas con resistencia a drogas.
EP2288727B1 (en) * 2008-05-14 2013-07-10 Genomic Health, Inc. Predictors of patient response to treatment with egf receptor inhibitors
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
BRPI1007048A2 (pt) * 2009-01-15 2016-02-10 Lab Corp America Holdings método e kit para correlacionar os níveis relativos da quantidade de pelo menos um de her-2 ou homodímeros de her-2 em uma amostra biológica de um indivíduo, e , método para prognosticar se um indivíduo com câncer e que é tratado com um agente que atua em her-2 é provável ter um evento significante.
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US9518988B2 (en) * 2010-04-18 2016-12-13 Yeda Research And Development Co. Ltd. Antibodies and methods of using same for treating ErbB/ErbB ligands associated diseases
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
LT2661266T (lt) * 2011-01-07 2020-12-10 Anji Pharma (Us) Llc Gydimo būdai chemosensorinio receptoriaus ligando pagrindu
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
AU2012318541B2 (en) * 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
MY194408A (en) 2011-10-14 2022-11-30 Genentech Inc Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab
CN110693867A (zh) 2012-01-06 2020-01-17 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
CN104254325A (zh) 2012-01-06 2014-12-31 埃尔舍利克斯治疗公司 双胍组合物和治疗代谢性病症的方法
TWI554284B (zh) 2013-04-16 2016-10-21 建南德克公司 帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估
AU2014296288B2 (en) * 2013-07-31 2020-02-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using PTH-related and EGF-related molecules
EP2876442A1 (en) * 2013-11-22 2015-05-27 Institut de Cancérologie de l'Ouest Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
RU2020120593A (ru) 2014-04-25 2020-09-01 Дженентек, Инк. Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
CA2955456A1 (en) 2014-07-17 2016-01-21 Brian J. Czerniecki Identification of immunogenic mhc class ii peptides for immune-based therapy
WO2016196373A2 (en) 2015-05-30 2016-12-08 Genentech, Inc. Methods of treating her2-positive metastatic breast cancer
EP3325005A4 (en) * 2015-07-17 2019-03-27 Brian J. Czerniecki IDENTIFICATION OF IMMUNOGENIC MHC CLASS II PEPTIDES FOR IMMUNO-BASED THERAPY
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN105403704A (zh) * 2015-12-31 2016-03-16 苏州市博纳泰科生物技术有限公司 Her-2的荧光免疫层析检测方法及试剂盒
WO2018085513A1 (en) 2016-11-04 2018-05-11 Genentech, Inc. Treatment of her2-positive breast cancer
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
CN117752782A (zh) 2017-01-17 2024-03-26 豪夫迈·罗氏有限公司 皮下her2抗体配制剂
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
CN110536969A (zh) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 跨膜或近膜域中的erbb2/her2突变
AU2019272190B2 (en) * 2018-05-25 2022-12-01 Bioneer Corporation Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
KR20250151568A (ko) 2020-06-29 2025-10-21 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합
JP2025527321A (ja) * 2022-08-09 2025-08-20 ヘリジェニクス インコーポレイテッド 遺伝分散の臨床的関連性を評価するための方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
CA2269204C (en) 1996-10-18 2012-01-24 Genentech, Inc. Anti-erbb2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
RU2270029C2 (ru) 1999-06-25 2006-02-20 Джинентех, Инк. ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ ОБЛАДАЕТ СПОСОБНОСТЬЮ СВЯЗЫВАТЬ ErbB2 И БЛОКИРОВАТЬ АКТИВАЦИЮ ЛИГАНДОМ РЕЦЕПТОРА ErbB (ВАРИАНТЫ) И КОМПОЗИЦИЯ ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ РАКА, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО
DK3115470T3 (en) 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
EP2263691B1 (en) 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
ES2246191T1 (es) * 2002-12-11 2006-02-16 Ventana Medical Systems, Inc. Metodo para predecir la respuesta a la terapia dirigida a her2.
AU2004211955B2 (en) 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
WO2004087887A2 (en) 2003-04-01 2004-10-14 Monogram Biosciences, Inc. Intracellular complexes as biomarkers
MXPA05012939A (es) 2003-05-30 2006-05-17 Astrazeneca Uk Ltd Procedimiento.
WO2005011607A2 (en) 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
JP2007512807A (ja) 2003-10-28 2007-05-24 バイエル ヘルスケア アーゲー 悪性腫瘍の処置に対する応答予測のための方法および組成物
TWM256978U (en) * 2004-04-02 2005-02-11 Nventec Appliances Corp Electronic device
US20060121044A1 (en) * 2004-12-07 2006-06-08 Genentech, Inc. Selecting patients for therapy with a her inhibitor
RU2300111C2 (ru) * 2005-06-15 2007-05-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ прогнозирования течения заболевания раком молочной железы

Also Published As

Publication number Publication date
JP2009504142A (ja) 2009-02-05
MA31549B1 (fr) 2010-08-02
RS51859B (sr) 2012-02-29
US20100112603A1 (en) 2010-05-06
RU2408735C2 (ru) 2011-01-10
KR20110074921A (ko) 2011-07-04
PT1915460E (pt) 2011-03-17
CL2010000720A1 (es) 2010-12-03
EP1915460B1 (en) 2010-12-29
ATE539171T1 (de) 2012-01-15
ATE493514T1 (de) 2011-01-15
AR057323A1 (es) 2007-11-28
EP2196547B1 (en) 2011-12-28
CR9686A (es) 2008-02-20
CA2616913A1 (en) 2007-02-22
CY1111612T1 (el) 2015-10-07
CN101705287A (zh) 2010-05-12
WO2007019899A8 (en) 2010-08-05
HRP20110171T1 (hr) 2011-04-30
ZA201102688B (en) 2012-01-25
AU2006281746B2 (en) 2011-06-23
CN101405405A (zh) 2009-04-08
NO20080371L (no) 2008-05-09
EP2196547A1 (en) 2010-06-16
MX2008001926A (es) 2008-03-24
AU2011202339A1 (en) 2011-06-09
TW200741010A (en) 2007-11-01
US7700299B2 (en) 2010-04-20
UA93989C2 (ru) 2011-03-25
PL1915460T3 (pl) 2011-05-31
ECSP088171A (es) 2008-03-26
NZ565270A (en) 2011-05-27
ES2356066T3 (es) 2011-04-04
RU2010115252A (ru) 2011-10-27
KR20080034922A (ko) 2008-04-22
DK1915460T3 (da) 2011-01-31
RU2008108907A (ru) 2009-09-20
SI1915460T1 (sl) 2011-04-29
AU2006281746A1 (en) 2007-02-22
DE602006019265D1 (de) 2011-02-10
US20070037228A1 (en) 2007-02-15
EP1915460A2 (en) 2008-04-30
BRPI0615001A2 (pt) 2011-04-26
WO2007019899A3 (en) 2007-04-05
WO2007019899A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
IL188923A0 (en) Method for predicting the response to a treatment
GB0504774D0 (en) Method
EP1864785A4 (en) SETEROLITHOGRAPHIEVERFAHREN
GB0503836D0 (en) Method
GB0512214D0 (en) Method
GB0519303D0 (en) Chemo-immunotherapy method
GB0520375D0 (en) Method
GB0504096D0 (en) Method
GB0509433D0 (en) Method
GB0504184D0 (en) Method
GB0507123D0 (en) Method
GB0520235D0 (en) Method
GB0510536D0 (en) Method
GB0502046D0 (en) Method
GB0508420D0 (en) Method
GB0515695D0 (en) Method
GB0505756D0 (en) Method
GB0509305D0 (en) Method
GB0509437D0 (en) Method
GB0520981D0 (en) Method
GB0518667D0 (en) Method
GB0504182D0 (en) Method
GB0509956D0 (en) Method
GB0506670D0 (en) Method
GB0502360D0 (en) Method